Accessibility
Contact

Canada FR EN

Current website:

Fresenius Kabi Canada EN

Suggested websites based on your location:

Fresenius Kabi USA - We Are Committed to Life

Global Website:

Fresenius Kabi Global Website

Fresenius Kabi around the world

Africa & Middle East
- MENA
- South Africa
Asia Pacific
- Australia
- China
- China (Hong Kong SAR)
- India
- Indonesia
- Japan
- Korea
- Malaysia
- New Zealand
- Philippines
- Singapore
- Taiwan
- Thailand
- Vietnam
Europe
- Austria
- Belgium
- Croatia
- Czech Republic
- Denmark
- Finland
- France
- Germany
- Great Britain
- Hungary
- Ireland
- Italy
- Netherlands
- Norway
- Poland
- Portugal
- Romania
- Russian Federation
- Slovakia
- Spain
- Sweden
- Switzerland
Latin America
- Argentina
- Brazil
- Chile
- Colombia
- Ecuador
- Mexico
- Peru
North America
- Canada
- USA

Fresenius Group

Company
- Main menu Company
  Learn about Fresenius Kabi both globally and locally
  - Company About Us
    About Us page
Products & Services
- Main menu Products & Services
  Discover Fresenius Kabi Canada's Products & Services
  - Products & Services Biosimilars
    Biosimilars section
  - Products & Services IV Drugs
    IV Drugs section
  - Products & Services Medical Nutrition
    Parenteral Nutrition section
  - Products & Services Animal Health
    Animal Health section
  - Products & Services Colloids
    Colloids
  - Products & Services Infusion Technology
    Infusion Technology section
  - Products & Services Transfusion Technology
    Transfusion Technology section
  - Products & Services Compounding
    Compounding
  - Products & Services Standard Solutions
    Standard Solutions section
Careers
- Main menu Careers
  Careers page

What are you looking for?

News

Filter by year

#total results found

January 8, 2025
Fresenius Kabi Canada has received a Health Canada Notice of Compliance (NOC) for Otulfi™ an Ustekinumab Biosimilar

Fresenius Kabi Canada has received a Health Canada Notice of Compliance (NOC) for Otulfi™* an Ustekinumab Biosimilar
October 23, 2024
Methotrexate for Injection, USP 1 gram per vial

Methotrexate for Injection, USP 1 gram per vial
October 21, 2024
Fresenius Kabi launches Tyenne®*, the first and only approved tocilizumab biosimilar in Canada

Fresenius Kabi launches Tyenne®*, the first and only approved tocilizumab biosimilar in Canada
October 11, 2024
Importation of Fresenius Kabi’s US-authorized Pantoprazole Sodium for Injection, 40 mg per vial

Importation of Fresenius Kabi’s US-authorized Pantoprazole Sodium for Injection, 40 mg per vial
October 11, 2024
Pantoprazole for Injection 40 mg SD Vial 10 mL US-Approved Product – Now Available

Pantoprazole for Injection 40 mg SD Vial 10 mL US-Approved Product – Now Available
May 31, 2024
Importation of Fresenius Kabi’s US-authorized Moxifloxacin Injection

Importation of Fresenius Kabi’s US-authorized Moxifloxacin Injection
May 31, 2024
Fighting Against Forced Labour and Child Labour in Supply Chains Act, S.C. 2023, c. 9 Annual Report

Fighting Against Forced Labour and Child Labour in Supply Chains Act, S.C. 2023, c. 9 Annual Report
January 18, 2024
Medical Device Recall – Type III – IV Infusion Sets Label Discrepancy

Medical Device Recall – Type III – IV Infusion Sets Label Discrepancy
December 1, 2023
NEW! Now you can subscribe to our communications

NEW! Now you can subscribe to our communications
October 25, 2023
Fresenius Kabi Canada: Partners in Health with HPIC for 15 years

Fresenius Kabi Canada: Partners in Health with HPIC for 15 years
September 28, 2023
Elonox® is now available on every provincial formulary in Canada

Elonox® is now available on every provincial formulary in Canada
September 19, 2023
Zinc Sulfate Injection, USP New Product Launch

Zinc Sulfate Injection, USP New Product Launch
August 28, 2023
Sodium Citrate 4% solution, USP, 250mL – New Product Launch

Sodium Citrate 4% solution, USP, 250mL – New Product Launch
February 23, 2023
Important Safety Information Sodium Acetate Injection, USP - Potential for the Development of Particulate Matter

Important Safety Information Sodium Acetate Injection, USP - Potential for the Development of Particulate Matter
May 17, 2022
Fentanyl Citrate Injection, USP 50 mcg/mL 20 mL SD Vial New Product Launch

Fentanyl Citrate Injection, USP 50 mcg/mL 20 mL SD Vial New Product Launch
November 26, 2021
Fentanyl Citrate Injection, USP 50 mcg/mL New Product Launch

Fentanyl Citrate Injection, USP 50 mcg/mL New Product Launch
September 30, 2021
HYDROmorphone Hydrochloride Injection, USP 10 mg/mL 50 mL New Product Launch

HYDROmorphone Hydrochloride Injection, USP 10 mg/mL 50 mL New Product Launch
September 7, 2021
Fresenius Kabi’s tocilizumab biosimilar candidate MSB11456 shows positive results in two clinical trials

Fresenius Kabi’s tocilizumab biosimilar candidate MSB11456 shows positive results in two clinical trials
September 2, 2021
Voriconazole for Injection 200 mg/vial New Product Launch

Voriconazole for Injection 200 mg/vial New Product Launch
June 24, 2021
Vinorelbine Injection, USP 10 mg/mL 5 mL Vials Product Launch

Vinorelbine Injection, USP 10 mg/mL 5 mL Vials Product Launch
February 19, 2021
Fresenius Kabi Canada Launches IDACIO®

Fresenius Kabi Canada Launches IDACIO®
December 19, 2020
Important Safety Information Bacitracin for Injection (50,000 IU per vial) – Risk of Nephrotoxicity and Anaphylactic Reactions

Important Safety Information Bacitracin for Injection (50,000 IU per vial) – Risk of Nephrotoxicity and Anaphylactic Reactions

Products & Services
Product Updates
Company
Contact Fresenius Kabi Canada

Terms of Use
Data Protection
Imprint

© Fresenius Kabi Canada Ltd. 2025